



*In the name of Allah  
The Compassionate, The Merciful*



6<sup>th</sup>  
International Tehran Hepatitis Conference



## Held by



Iran Hepatitis  
Network  
[www.Hep.ir](http://www.Hep.ir)

Iran Hepatitis Network



The Brilliant Future  
of Publishing  
[www.KowsarPub.com](http://www.KowsarPub.com)

Kowsar Corporation



Baqiyatallah Research Center for  
Gastroenterology and Liver Disease

Baqiyatallah Research Center for Gastro-  
enterology and Liver Diseases

## Conference Venues

- ▶ **Main Part:** 27-29 May 2015, Razi Convention Center, Iran University of Medical Sciences, Tehran, Iran.
- ▶ **Additional Day:** 30 May 2015, Sina and Sadra Hall, Shiraz University of Medical Science, Shiraz, Iran.

## THC6 Secretariat

- ▶ **Address:** NO. 178, Shadab Cross, Sepahbod Gharani St, Tehran, Iran.  
Telephone: 98-21-81262072, 98-21-88614523, 98-21-88945186-7  
Fax: 98-21-81262072, 98-21-88945188  
Postal Box: 14155-3651  
Email: [info@hep.ir](mailto:info@hep.ir) & [info@thc6.ir](mailto:info@thc6.ir)  
[Chairman@meldcenter.com](mailto:Chairman@meldcenter.com)  
[info@hepcomm.com](mailto:info@hepcomm.com)  
Website: [THC6.ir](http://THC6.ir)

# Table of Contents

Welcome Message .....	5
About Tehran .....	8
THC6 Boards and Committees .....	10
THC6 Internationally Invited Speakers .....	12
International KOWSAR Award .....	15
Yas Young Investigator Award .....	18
THC6 Program at a Glance .....	20
Scientific Program - Hall A .....	24
Scientific Program - Hall B .....	28
Scientific Program - Hall C .....	33
Scientific Program - Additional Day (Shiraz) .....	37
THC6 Workshops .....	38
Poster Presentations .....	39
Congress Online .....	48

*6<sup>th</sup> International Tehran Hepatitis Conference*

## Welcome Message

**Dear colleagues,**

As the director of Iran Hepatitis Network and Global Hepatitis Community, I would like to mention that viral hepatitis is one of our priority in health-care system now. The burden of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in the region mandates us to work more in this issue. We made a link between epidemiologists, clinicians, pathologists, virologists, specialists in transfusion medicine as well as research and laboratory centers from Iran and the world. We would like to facilitate scientific communication between researchers who are working in the field of viral hepatitis and other liver diseases. One of our activity is Tehran Hepatitis Conference which has been held for 5 times yet in Tehran, Iran.



I would like to take great pleasure in inviting you to participate in the 6<sup>th</sup> International Tehran Hepatitis Conference (THC6) hosted by Iran Hepatitis Network which will take place in Iran, May 2015. In THC5, around 1500 scientists participated and we had distinguished speakers from Canada, South Korea, Germany and the region. I invite all universities, research centers and other scientific professions in hepatology and liver diseases to join us.

**Kind Regards,**

**Seyed-Moayed Alavian, M.D.**  
**THC6 Chairman**  
**Professor of Gastroenterology and Hepatology**  
Director of Iran Hepatitis Network  
Tel/Fax: +98 21 8126 2072  
Tehran, I.R. Iran  
editor@hepatmon.com / alavian@thc.ir

## رسالة ترحيب

### أعزائي الزملاء

نود أن ندعوكم الى المشاركة في مؤتمر طهران الدولي السادس للتهباتيت، الذي تقيمه شبكة الهباتيت في إيران والمزمع عقده في إيران، في العام ٢٠١٥.

في مؤتمر طهران الدولي الخامس للتهباتيت شارك ما يقارب الـ ١٥٠٠ عالم، وقد حضر المؤتمر محققون من كندا، كوريا الجنوبية، ألمانيا والبلدان المجاورة.

بإمكانكم إرسال خلاصة مقالاتكم الى المؤتمر عبر الموقع التالي:

[www.thc6.ir](http://www.thc6.ir). سيقوم فريق اللجنة العلمية في التدقيق في الخلاصات المرسله، ليتم من بعد ذلك الإعلان عن الخلاصات التي تم الموافقة عليها لتقديم عرض شفهي أو ملصق نموذجي للمقالة.

نحن نتطلع إلى الاستمتاع معكم بالبرنامج العلمي القوي والجذاب، الذي سيتضمن كل جوانب وجميع التطورات الأخيرة في جميع تخصصات التهاب الكبد الفيروسي. البرامج العلمية التمهيدية متاحة على الموقع الرسمي لمؤتمر طهران الدولي السادس للتهباتيت.

مع أطيب الأمنيات

الدكتور سيد مؤيد علويان.

المدير العلمي لمؤتمر طهران الدولي السادس للتهباتيت

أستاذ في الجهاز الهضمي والكبد

مدير شبكة الهباتيت في إيران

هاتف / فاكس: ٨١٢٦٢٠٧٢ - ٢١ (+٩٨)

طهران، الجمهورية الإسلامية في إيران

*6<sup>th</sup> International Tehran Hepatitis Conference*

**karsilama Mesaji**

Siz altıncı beynəlxalq Təhran hepatit (THC6) konfransında iştirak etmək üçün dəvət edirsiniz. Bu konfrans İran Hepatit Şəbəkəsi tərəfindən 2015 -ci ildə keçiriləcəkdir.

Beşinci beynəlxalq Təhran hepatit (THC5) konfransı 2013-ildə Təhran şəhərində təşkil edilmişdi və təxminən 1500 alim və məruzəçilər Kanada, Cənubi Koreya, Almanya və digər ölkələrdən iştirak etmişdilər.

Sizi də dəvət edirik ki, məqalələrinizin xülasələrini konfransın “ [www.thc6.ir](http://www.thc6.ir)” internet saytı vasitəsilə bizim üçün göndərin. Sizin məqalələrinizin xülasələri konfransın elmi komitəsi tərəfindən dəyərləndirilməli və onların qərarı ilə məruzə və ya məqalə üçün qəbul ediləcəkdir.

Bu vəs ilə viruslu hepatit sahəsində bütün istiqamətlər və son inkişaf daxil olmaqla güclü və cazibədar elmi proqramlarda əməkdaşlıq etmək üçün, sizi dəvət edirik.

İlk elmi proqramlar konfransın “ [www.thc6.ir](http://www.thc6.ir)” rəsmi veb saytında mövcuddur.

Dr. Seyid Müəyyid Alavian

THC6 nin Elmi Direktoru

Gastroenterolojivə Hepatoloji Professoru

İran Hepatit şəbəkəsinin başçısı

Tel / Fax: +98 21 81262072

Təhran / İran

## About Tehran

Tehran is the capital and largest city of I.R. Iran, and the administrative center of Tehran Province. Tehran is a sprawling city at the foot of the Tochal mountain range with an immense network of highways unparalleled in Western Asia. The city is famous for its numerous resorts on the Alborz slopes, large museums, art centers, and palace complexes. Tehran is the largest city in the Middle East and is the 16th most populated city in the world with a population of around 7,800,000 people. Most Iranian industries are headquartered in Tehran, including the manufacturing of automobiles, electrical equipment, military weaponry, textiles, sugar, cement, and chemical products. Tehran is also a

leading center for the sale of carpets and furniture. There is an oil refinery located south of the city. In the 20<sup>th</sup> century, Tehran faced a large migration of people from all around I.R. Iran. Today, the city contains various religious minorities, and has many historic mosques, churches, synagogues and Zoroastrian fire temples. Contemporary Tehran is a modern and expensive city featuring many skyscrapers, of which the Azadi Tower and the Milad Tower have come to be symbols of Tehran itself.



## History



The origin of the name Tehran is unknown. Excavations place the existence of settlements in Tehran as far back as 6000 BC. Tehran was well known as a village in the 9<sup>th</sup> century, but was less well-known than the city of Rhages (Ray) which was flourishing nearby in the early era. In the 13<sup>th</sup> century, following the destruction of Ray by Mongols, many of its inhabitants escaped to Tehran. In some sources of the early era, the city is mentioned as "Rhages's Tehran". The city is later mentioned in Hamdollah Mostowfi's *Nuz'hat al-Qulub* (written in 1340) as a famous village. Don Ruy Gonzáles de Clavijo, a Castilian ambas-



**6<sup>th</sup> International Tehran Hepatitis Conference**

sador, was probably the first European to visit Tehran, stopping in July 1404, while on a journey to Samarkand (now in Uzbekistan) and the Mongol capital at the time. At this time, the city of Tehran was unwallled. Tehran became a residence of the Safavid rulers in the 17<sup>th</sup> century. Tahmasp I built a bazaar and a wall around the city, but it somewhat fell out of favor after Abbas I turned sick when he was passing the city to go to a war with the Uzbeks. In the early of 18<sup>th</sup> century, Karim Khan Zand ordered a palace, a harem, and a government office to be built in Tehran, possibly to declare the city his capital, but later moved his government to Shiraz. Tehran finally became the capital of I.R. Iran in 1795, when the Qajar king Agha Mohammad Khan was crowned in the city. It remains the capital to this day.

**Climate**



Tehran's climate is largely defined by its geographic location, with the towering Alborz Mountains to its North and the central desert to the South. It can be generally described as mild in the spring, hot and dry in the summer, pleasant in the autumn, and cold in the winter. As a large city with a significant differ-

ences in elevation among various districts, the weather is often cooler in the hilly north as compared to the flat southern part of Tehran. Summer is usually hot and dry with very little rain, but relative humidity is generally low and the nights are cool. The majority of the light annual precipitation occurs from late-autumn to mid-spring, but no one month is particularly wet. The hottest month is July (mean minimum temperature 23°C, mean maximum temperature 36°C) and the coldest is January (mean minimum temperature -1°C, mean maximum temperature 8°C). Although compared with other parts of the country Tehran enjoys a moderate climate, weather conditions can sometimes be unpredictably harsh. The record high temperature is 48°C and the record low is -20°C.

## THC6 Boards and Committees

*Held by:*

Iran Hepatitis Network  
Kowsar Corporation  
Baqiyatallah Research Center for Gastroenterology and Liver Disease

*THC6 Governing Board:*



Prof. Seyed-Moayed Alavian, MD, Director of Iran Hepatitis Network, Tehran, IR Iran



Prof. Kamran Bagheri-Lankarani, MD, Shiraz University of Medical Sciences, Shiraz, IR Iran



Prof. Frank Tacke, MD, PhD, University Hospital Aachen, Aachen, Germany

*Executive Manager:*



Dr. Heidar Sharafi, PhD, Iran Hepatitis Network, Tehran, IR Iran

*Scientific Coordinator:*

Khshayar Hesamizadeh, MSc

*Basic Science Managers:*

Seyed Mohammad Jazayeri, MD, PhD

Seyed Mohammad Miri, MD, PhD

*International Affairs & Communication Manager:*

Monir Niazi, Manager of Gastroenterology and Hepatology Center, Tehran, IR Iran  
Leila Mehrnoush, MD Hepatology International Affair Manager / Iran - Azerbaijan  
Shima Salimi, MD Coordinator for communication with DIC and MMT centers

*Scientific Committee:*

Adibi P, MD

Alavian SM, MD

Ataei B, MD

Alavi-Moghaddam M, MD

Behnava B, MD

Einollahi B, MD

Fattahi MR, MD

HasanjaniRoshan MR, MD

Jazayeri SM, MD

Jariyani A, PhD

Hajarizadeh B, MD, PhD

Karimi-Sari H, MD

Keshvari M, MD

Keyvani H, PhD

Lankarani KB, MD

Mahboobi N, DDS

Mansouri S, MD

Mansour-Ghanaei F, MD

Mardani M, MD

Merat S, MD

Mohammad-Nejad M, MD

Miri SM, MD, PhD

Nabavi M, MD

Naseri Moghadam S, MD

Nikbin M, MD

Pourhoseingholi MA, PhD

Roohvand F, PhD

Saberi Firooz M, MD

Sali S, MD

Sayyad B, MD

Seyfi Zareie B, MD

Somi M, MD

Sharafi H, PhD

Shekarabi M, MD

Yadegari D, MD

Zamani F, MD

**6<sup>th</sup> International Tehran Hepatitis Conference**

***IT Committee:***

Meisam Fathi, Head  
Javad Karimi  
Shahnaz Yari  
Samira Nateghi  
Rahim Asgari  
Mehdi Fathi  
Roya Noraei  
Peyman Palizgir

***Executive Committee:***

Mehdi Ashour  
Mohammad Ali Sarami  
Seyed Abbas Alavian  
Seyed Ehsan Alavian  
Vahid Haghani  
Farshad Abdolrahimi  
Shahla Bordbar  
Saeedeh Ebadat  
Maryam Ahmadi  
Samira Ahmadi  
Arezo Mirzaee  
Marzieh Taheri  
Amir Hesam Nemati  
Hosein Noroozian  
Majid Asgari  
Mohammad Taghi Borjian  
Bahman Aghcheli  
Saeed Ghorbani

***Secretariat Committee:***

Bent-al-Hoda Beyram, Head  
Elham Jannati  
Maryam Nima  
Maryam Padami

***Students' (Young Investigator) Scientific Committee:***

Hamidreza Karimi-Sari, Head  
Maani Beigy  
Reza Ajudani  
Elham Maserat  
Masoome Rezaee asl  
Fardin Dolatimehr  
Mohammad Hossein Khosravi  
Farhad Pishgar  
Mahdi Faridchehr  
Sarvenaz Shaaheen  
Sarah Ala  
Maryam Tajik  
Mahdi Safiabadi

Mohammad Saeid Rezaee-Zavareh  
Mohammad Ehsan Bayatpoor

***Editorial Board:***

Abtahi H, MD  
Akhavan niaki H, MD  
Alavi SM, MD  
Aflatoonian MR, MD  
Agha Sadeghi MR, MD  
Aghazadeh R, MD  
Ayatollahi J, MD  
Davoodian P, MD  
Ebrahimi Daryani N, MD  
Fattahi Abdizadeh M, PhD  
Godarzi MT, MD  
Golsha R, MD  
Hashemi Tabar M, MD  
Hoseini A, MD  
Joghataee MT, PhD  
Kalantari H, MD  
Karimzadeh H, PhD  
Khaleghi nia S, MD  
Malekzadeh R, MD  
Mardani M, MD  
Metanat M, MD  
Mirmajlesi H, MD  
Mohraz M, MD  
Mohammadzadeh M, MD  
Monavari HM, PhD  
Motezaker M, MD  
Naghili B, MD  
Naser poor T, MD  
Nassiri-Toosi M, MD  
Piroozi A, MD  
Rafiee AR, MD  
Ranjbar R, PhD  
Saneie Moghadam E, DCLS  
Semnani S, MD  
Shahbazi M, MD  
Shahi H, MD  
Sheikh Esmaeli F, MD  
Soltani Tehrani B, MD  
Tavalaei M, MD  
Vahdat K, MD  
Yadegari nia D, MD  
Zali MR, MD  
Ziaie M, MD

## THC6 Internationally Invited Speakers



Bijan Eghtesad,  
*USA*



Frank Tacke,  
*Germany*



Hadi Karimzadeh,  
*Germany*



Maryam Salehi Alavi,  
*Australia*



Robert Gish,  
*USA*




Hubert Blum,  
*Germany*



Jason Grebely,  
*Australia*



Mario Mondelli,  
*Italy*



Maria Rendina,  
*Italy*



Markus Peck-Radosavljevic,  
*Austria*



Behzad Hajarizadeh,  
*Australia*



Mohammad Sajjad Rahnama'I,  
*Netherlands*



Blaine Hollinger,  
*USA*



Pascal Pineau,  
*France*



Pietro Lampertico,  
*Italy*



Peter Karayiannis,  
*UK*



Cihan Yurdaydin,  
*Turkey*



Hatef Masoumi,  
*USA*



Gregory Dore,  
*Australia*



Peter Ferenci,  
*Austria*



Marek Jan Los,  
*Sweden*



Philippe Roingeard,  
*France*



Azzam Kayasseh,  
*UAE*



Behzad Yeganeh,  
*Canada*



Michael Roggendorf,  
*Germany*



Massimo Colombo,  
*Italy*



Ashley Brown,  
*UK*



Siamak Seddigh-Tonekaboni,  
*UK*



Mahmoudreza  
Pourkarim,  
*Belgium*



Mario Rizeo,  
*Italy*



## International KOWSAR Award

The International Kowsar Award in Hepatology is an international scientific award, which for the first time in history is going to be presented to top researchers with lifelong experience in the field of hepatology, who have extended our knowledge and understanding of the epidemiological aspects, the pathobiological mechanisms, new therapeutics and the molecular basis for the diagnosis and treatment of liver diseases, particularly viral hepatitis, up until the present time, or to those researchers who are likely to do so, in our estimation, in the future. This award was established by Prof. Seyed-Moayed Alavian, Professor of Gastroenterology and Liver Diseases and Editor-in-Chief of the Hepatitis Monthly journal, the only specialized journal pertaining to liver diseases in the Middle East and central Asia, and with the cooperation of Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL).



### **The Kowsar Award 2009**

The Kowsar award 2009 was conferred on Prof. Mario Rizzetto, Professor of Gastroenterology and Liver Diseases at the University of Torino, Italy, who was the discoverer of the delta antigen and antibody in carriers of the hepatitis B surface antigen.



### **The Kowsar Award 2010**

The Winner of the Kowsar International Hepatology Award 2010 was Prof. Dr. Med. Michael Roggendorf, Professor of Hepatology at the University of Essen, Germany.



### **The Kowsar Award 2011**

The Winner of the Kowsar International Hepatology Award 2011 was Prof. Howard Thomas.



### **The Kowsar Award 2013**

The Winner of The Kowsar Award 2013 was Prof. Daniel Lavanchy, Honorary Member at Viral Hepatitis Prevention Board (VHPB), Geneva Area, Switzerland.



## Kowsar Award 2015

**In the Name of Allah  
the Compassionate, the Merciful**

Islamic Republic of Iran  
Iran Hepatitis Network

**Dear Professor Peter Karayiannis,**

In recognition of your outstanding achievements in the scientific world, your contribution to human health and prosperity, and your time efforts in medical sciences on general, I am in the privileged position to present to you on behalf of the Iran hepatitis Network and Baqiyatallah Research Center for Gastroenterology and Liver Diseases the

**International Kowsar Award, 2015 in THC6 in Tehran.**

Your contribution scientifically to the field of hepatology, including the effect of HBV variants arising during the natural history of the infection on long term disease outcome and those arising as a result of human intervention, such as through vaccination or antiviral treatment, as well as new approaches to treatment, evasion of the immune response during chronic infection, have been considerable and extensive over years. Furthermore, your activities as the Editor for the Journal of Viral Hepatitis for many years have greatly added to our understanding of these fields and have helped scientists and clinicians all over the world. It is an honor for Iranian scientific community to recognize your exceptional endeavors and accomplishments. We pray for continued success in your services to humanity, and wish your prosperity and good health.

*Alavia*

**Professor Seyed Moayed Alavian,  
Chairman of 6th International Tehran Hepatitis Conference,  
27-30 May 2015,  
Tehran, IR Iran**

**6<sup>th</sup>**

**International Tehran Hepatitis Conference**





## Biography of KOWSAR Award Winner




Prof. Peter Karayiannis, BSc, PhD, FIBMS, FRCPath  
Peter Karayiannis is Professor of Microbiology/Molecular Virology at the University of Nicosia Medical School and holds an honorary appointment with St George's Hospital Medical School, University of London. Professor Karayiannis holds a PhD in Medical Microbiology from the Liverpool University. He is a Fellow of the Institute of Biomedical Sciences (FIBMS) and a Fellow of the Royal College of Pathologists [FRCPath (Virol)].

Professor Karayiannis joined the University of Nicosia in September 2013, having previously worked at the Department of Medical Microbiology, Liverpool University (1976-1981), Department of Medicine, Royal Free Hospital Medical School (1981-1987), Department of Medicine, St Mary's Hospital Medical School (1987-1995) and the Hepatology Section, St Mary's Campus, Imperial College London (1995-2012).



His research interests are concerned with the hepatitis viruses, predominantly B and C (HBV, HCV) and include the study



of the mechanisms that favour viral persistence and evasion of the immune response during chronic infection, the effect of HBV variants arising during the natural history of the infection on long term disease outcome and those arising as a result of human intervention, such as through vaccination or antiviral treatment, as well as new approaches to treatment. Other research interests include studies on the basic molecular biology of both HBV and HCV, the role of various viral proteins in the replication of the viruses, possible interference with cellular biosynthetic or defense pathways, as well as their role in hepatocarcinogenesis. More recently, his research work has concentrated on the role of genomic HCV mutations that have been identified in isolates from immune privileged sites such as peripheral blood mononuclear cells and brain tissue, and the effect of such mutations on the replication capacity of infectious clones of the virus. He is European Editor for the Journal of Viral Hepatitis and on the editorial board of a number of other journals. He has authored well over 200 original papers and reviews published in peer reviewed journals and books.

## **Yas Young Investigator Award**

As the important impact of young people in the science, we should encourage them to be more active in this field. We had five Tehran Hepatitis Conferences (THCs) yet and many participants from Iran, the region and other parts of the world. Many of them were young investigators. We would like to attract the young people to participate actively in the conference and research activities in field of hepatology.

The “Yas Young Investigator Award” in Hepatology is a scientific award, which for the first time in history is going to be presented to top young researchers with novel experiences in the field of hepatology, who designed an integrated a new modalities for diagnosis and treatment of liver diseases, publishing original articles with high impact factor, sharing the experiences with others, and to be more active in social support of patients. This award was founded in 2015 by Prof. Seyed-Moayed Alavian, Professor of Gastroenterology and liver disease and editor-in-chief of the Hepatitis Monthly Journal, the only specialized journal pertaining to liver disease in the Middle East and central Asia.



## Biography of YAS Award Winner



Christine Hartoonian holds a Pharm.D. and a Ph.D. in Pharmaceutical Biotechnology. Her main focuses in research and on both grade dissertations were on HCV vaccine models adjuvanted by several molecular immunomodulators.

Christine was born in an educated Iranian-Armenian family in Tehran. Being deeply interested in infectious disease and genetics since the very years of guidance school, she had the interest of reading graduate school text books in fields of genetics and microbiology throughout school years, which resulted in her future field of studies. In 2000 entered the Faculty of Pharmacy, Pharmaceutical Sciences Unit of Tehran. Following her interests, she attended in the first Iranian Biotechnology Congress, where she was introduced to viral Hepatitis and DNA vaccination. During pharmacy school years, achieved the highest rank of the faculty in the “comprehensive exam of basic sciences of Pharmacy”. She just finally decided to challenge her abilities and enthusiasm in hepatitis DNA vaccination practically and designed her Pharm.D. thesis on HCV DNA vaccine model adjuvanted by molecular cytokines; GM-CSF and IL-23. Subsequently, entered the Ph.D. course of Pharmaceutical Biotechnology in Tehran University of Medical sciences to further improve her experience in HCV vaccine models. As Ph.D. thesis, designed a dual cassette based HCV DNA vaccine expressing core antigen and molecular chemokine CCL19, a robust DC function modulator, as genetic adjuvant. Alongside, evaluated adjuvant activity of MIP-3 $\alpha$  chemokine, combination of CCL19 and MIP3 and the novel class III IFN family member, IFN $\lambda$ 1, as genetic adjuvants for HCV DNA vaccine model. In association with her colleague, designed an intrahepatic delivery route for an HCV protein as vaccine model and evaluated its immunogenicity. During Ph.D. course in parallel, has participated in divergent projects as research assistant e.g. HBV therapeutic vaccine adjuvanted with a natural immunomodulator, antiviral activity and the mechanism behind the IFN $\alpha$  and IFN $\lambda$ , construction of r-Adenoviruses as means of regenerative medicine tools, HIV DNA vaccine model using nanoparticles and GM-CSF adjuvant. She has published articles, holds 2 patents and several abstracts in international congresses, being also available as external reviewer for a number of journals including Hepatitis Monthly. In 2007, was awarded as the best oral presenter in “The first Iranian clinical microbiology congress”. Her recent researches are mainly focused on molecular mechanisms behind Hepatocellular carcinoma and therapeutics for viral hepatitis related cancers. Having the belief that any scientific achievement couldn't be happened without team work, she is always grateful of her mentors and colleagues, Dr.M.Mahdavi, Dr.A.Arashkia, Dr.B.Negahdari and supervisors in Tehran University of Medical Sciences.

# THC6 Program at a Glance

HOURS
07:00-07:15
07:15-07:30
07:30-07:45
07:45-08:00
08:00-08:15
08:15-08:30
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:00
11:00-11:15
11:15-11:30
11:30-11:45
11:45-12:00
12:00-12:15
12:15-12:30
12:30-12:45
12:45-13:00
13:00-13:15
13:15-13:30
13:30-13:45
13:45-14:00
14:00-14:15
14:15-14:30
14:30-14:45
14:45-15:00
15:00-15:15
15:15-15:30
15:30-15:45
15:45-16:00
16:00-16:15
16:15-16:30
16:30-16:45
16:45-17:00
17:00-17:15
17:15-17:30
17:30-17:45
17:45-18:00
18:00-18:15
18:15-18:30

REGISTRATION		FIRST DAY-27 MAY			
		<b>OPENING CEREMONY</b>			
	Hepatitis B - Best of EASL <b>HA1</b>	Viral Hepatitis for Nurses-Hemodialysis <b>HB1</b>	Viral Hepatitis in People Who Inject Drug <b>HC1</b>	How to Write a Scientific Paper-Workshop <b>W1</b>	
		<b>Kowsar &amp; Yas Award Ceremony</b>			
		<b>Coffee Break</b>			
	Hepatitis C- Best Of EASL <b>HA2</b>	Viral Hepatitis For Nurses-Prevention <b>HB2</b>	Occult Viral Hepatitis <b>HC2</b>	How To Design A Basic Science Project-Workshop <b>W2</b>	
		<b>Lunch And Prayer</b>			
	Complications Of Viral Hepatitis-Best Of EASL <b>HA3</b>	Economics Burden Of Liver Diseases <b>HB3</b>	Viral Hepatitis & Host Genetics <b>HC3</b>	How to Design a Clinical Trial-Workshop <b>W3</b>	
		<b>Coffee Break</b>			
	Non-Viral Liver Diseases-Best Of EASL <b>HA4</b>	Epidemiology And Natural History Of Viral Hepatitis <b>HB4</b>	Update on HCV Vaccine <b>HC4</b>		

- Hall D
- Hall C
- Hall B
- Hall A

# THC6 Program at a Glance

HOURS
07:00-07:15
07:15-07:30
07:30-07:45
07:45-08:00
08:00-08:15
08:15-08:30
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:00
11:00-11:15
11:15-11:30
11:30-11:45
11:45-12:00
12:00-12:15
12:15-12:30
12:30-12:45
12:45-13:00
13:00-13:15
13:15-13:30
13:30-13:45
13:45-14:00
14:00-14:15
14:15-14:30
14:30-14:45
14:45-15:00
15:00-15:15
15:15-15:30
15:30-15:45
15:45-16:00
16:00-16:15
16:15-16:30
16:30-16:45
16:45-17:00
17:00-17:15
17:15-17:30
17:30-17:45
17:45-18:00
18:00-18:15
18:15-18:30

## SECOND DAY-28 MAY

### Meet With Professor

Prospects of Research on HCV Vaccines in the Era of DAAs  
**HA5**

Practical Guideline & Novel Therapeutic Approach to Chronic HBV  
**HB5**

Management of Hepatitis C  
**HC5**

### Coffee Break

Hepatology State of the Art Lectures, Second Day  
**HA6**

PWID & HCV  
**HA7**

Viral Hepatitis-Basic Studies  
**HB6**

Meta-Analysis Workshop  
**W4**

### Lunch And Prayer

The Era of New Hepatitis C DAAs; From West to East  
**HA8**

Noninvasive Methods of Diagnosing Hepatic Fibrosis  
**HB7**

Viral Hepatitis-Molecular Studies  
**HC6**

Meta-Analysis Workshop  
**W5**

### Coffee Break

From Probability to Certainty: Achieving Cure for All HCV Patients?  
**HA9**

Autoimmune Hepatitis- Postgraduate Course  
**HB8**

Liver Diseases in Middle Eastern and Central/Asian Countries  
**HC7**

# THC6 Program at a Glance

HOURS
07:00-07:15
07:15-07:30
07:30-07:45
07:45-08:00
08:00-08:15
08:15-08:30
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:00
11:00-11:15
11:15-11:30
11:30-11:45
11:45-12:00
12:00-12:15
12:15-12:30
12:30-12:45
12:45-13:00
13:00-13:15
13:15-13:30
13:30-13:45
13:45-14:00
14:00-14:15
14:15-14:30
14:30-14:45
14:45-15:00
15:00-15:15
15:15-15:30
15:30-15:45
15:45-16:00
16:00-16:15
16:15-16:30
16:30-16:45
16:45-17:00
17:00-17:15
17:15-17:30
17:30-17:45
17:45-18:00
18:00-18:15
18:15-18:30

## THIRD DAY-29 MAY

### Meet With Professor

Hepatitis B in Liver Transplantation, OBI, and Pregnant Women with Hepatitis B  
**HA10**

HIV/HCV Co-infection  
**HB9**

Viral Hepatitis and Blood Safety  
**HC8**

### Coffee Break

Hepatology State of the Art Lectures, Second Day  
**HA11**

Challenges in Viral Hepatitis; From Diagnosis to Management  
**HA12**

Hepatocellular Carcinoma: an Update  
**HB10**

An Approach toward Non-alcoholic Fatty Liver Disease (NAFLD)  
**HC9**

The Use of Social Media in Medicine  
**W6**

### Lunch And Prayer

Standard of the Care for Patients with Hepatitis C in 2015  
**HA13**

Strategic Programs of Viral Hepatitis Control in Iran  
**HB11**

The Role of Education in Prevention and Control of Liver Diseases  
**HC10**

# THC6 Program at a Glance

HOURS
07:00-07:15
07:15-07:30
07:30-07:45
07:45-08:00
08:00-08:15
08:15-08:30
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:00
11:00-11:15
11:15-11:30
11:30-11:45
11:45-12:00
12:00-12:15
12:15-12:30
12:30-12:45
12:45-13:00
13:00-13:15
13:15-13:30
13:30-13:45
13:45-14:00
14:00-14:15
14:15-14:30
14:30-14:45
14:45-15:00
15:00-15:15
15:15-15:30
15:30-15:45
15:45-16:00
16:00-16:15
16:15-16:30
16:30-16:45
16:45-17:00
17:00-17:15
17:15-17:30
17:30-17:45
17:45-18:00
18:00-18:15
18:15-18:30

## ADDITIONAL DAY (SHIRAZ)-30 MAY

General Discussion  
on Hepatitis  
**S1**

**Coffee Break**

Liver Transplantation and  
Hepatocellular Carcinoma  
**S2**

**Conclusion and Closing**

## Scientific Program - Hall A

► **First Day, 27<sup>th</sup> May, 2015**

### **HA1 Hepatitis B-Best of EASL**

08:00-09:50

#### **Titles and Speakers:**

- HBV: Current Treatment Option  
*Peter Karayannis (UK), 20 min*
- HBV: New Concepts for Eradication and Novel Therapeutics  
*Cihan Yurdaydin (Turkey), 20 min*
- HBV: Management of Antiviral Therapy in Liver Cirrhosis  
*Reza Malekzadeh (Iran), 20 min*
- Delta Hepatitis  
*Mario Rizzetto (Italy), 20 min*
- Discussion, 30 min

#### **Moderator:**

*Reza Malekzadeh*

#### **Members:**

*Peter Karayannis  
Cihan Yurdaydin  
Mario Rizzetto*

---

### **HA2 Hepatitis C-Best of EASL**

11:20-13:10

#### **Titles and Speakers:**

- HCV: New Treatment Options - DAA & Interferon  
*Mario Mondelli (Italy), 20 min*
- HCV: New Treatment Options - Interferon-Free Regimen  
*Peter Ferenci (Austria), 20 min*
- HCV: Special Populations (HIV and Renal Insufficiency)  
*Cihan Yurdaydin (Turkey), 20 min*
- HCV: Management of Patients with Thalassemia or Hemophilia  
*Seyed Moayed Alavian (Iran), 20 min*

- Discussion, 30 min

#### **Moderator:**

*Seyed Moayed Alavian*

#### **Members:**

*Mario Mondelli  
Peter Ferenci  
Cihan Yurdaydin*

---

### **HA3 Complications of Viral Hepatitis-Best of EASL**

14:00-15:50

#### **Titles and Speakers:**

- Liver Fibrosis: Invasive and Non-Invasive Assessment  
*Mario Rizzetto (Italy), 20 min*
- Liver Cirrhosis: Management of Decompensated Cirrhosis  
*Frank Tacke (Germany), 20 min*
- Complications of Liver Cirrhosis and Its Management-The Iranian Perspective  
*Nasser Ebrahimi Daryani (Iran), 20 min*
- Hepatocellular Carcinoma: Current Treatment Options  
*Markus Peck (Austria), 20 min*
- Discussion, 30 min

#### **Moderator:**

*Nasser Ebrahimi Daryani*

#### **Members:**

*Mario Rizzetto  
Frank Tacke  
Markus Peck*

---

### **HA4 Non-viral Liver Diseases-Best of EASL**

16:20-18:20



## Scientific Program - Hall A

### Titles and Speakers:

- Fatty Liver in Iran  
*Shahin Merat (Iran), 30 min*
- Autoimmune and Cholestatic Liver Diseases  
*Hubert Blum (Germany), 20 min*
- Management of Autoimmune Hepatitis  
*Siavosh Nasserri-Moghaddam (Iran), 20 min*
- Acute Liver Failure & Transplantation  
*Kamran Bagheri-Lankarani (Iran), 20 min*
- Discussion, 30 min

### Moderator:

*Siavosh Nasserri-Moghaddam*

### Members:

*Cihan Yurdaydin  
Shahin Merat  
Hubert Blum  
Kamran Bagheri-Lankarani*

## ▶ Second Day, 28<sup>th</sup> May 2015

### HA5 Prospects of Research on HCV Vaccines in the Era of DAAs

08:00-10:00

### Titles and Speakers:

- Introduction to HCV Vaccine Studies, Past, Present and Future Prospects  
*Farzin Roohvand (Iran), 25 min*
- Application of Bioinformatics for HCV Vaccine Designs  
*Mohammad-mehdi Ranjbar (Iran), 15 min*
- HCV Polytopic Vaccines  
*Katayoun Samimi-Rad (Iran), 15 min*
- Development of Bivalent HBV-HCV Prophylactic Vaccines  
*Philippe Roingeard (France), 20 min*
- Lessons from Improved HBV Vaccines for Developing an Effective HCV Vaccine  
*Michael Roggendorf (Germany), 20 min*

- Discussion, 25 min

### Moderator:

*Farzin Roohvand*

### Members:

*Mohammad-mehdi Ranjbar  
Katayoun Samimi-Rad  
Philippe Roingeard  
Michael Roggendorf*

---

### HA6 Hepatology State of the Art Lectures, Second Day

10:30-11:30

### Titles and Speakers:

- New Treatments in Hepatitis B Genotype D Patients  
*Pietro Lampertico (Italy), 25 min*
- Treatment of Hepatitis C in the Era of DAAs – Perspectives in Liver Transplantation  
*Bijan Eghtesad (USA), 25 min*
- Q & A, 10 min

---

### HA7 Enhancing Hepatitis C Prevention and Care for People Who Inject Drugs: Moving Towards Equitable Access for All

11:30-13:00

### Titles and Speakers:

- Strategies to Enhance HCV Treatment Uptake and Outcomes among People who Inject Drugs (PWID)  
*Jason Grebely (Australia), 15 min*
- Models of HCV Care for People who Inject Drugs: Insights from Australian Experiences  
*Maryam Alavi (Australia), 15 min*

## Scientific Program - Hall A

- HCV Treatment as Prevention among People who Inject Drugs

*Gregory Dore (Australia), 15 min*

- Epidemiology of Drug Use and HCV Infection among People who Inject Drugs in Iran

*Afarin Rahimi-Movaghar (Iran), 15 min*

- Discussion, 30 min

### Moderator:

*Behzad Hajarizadeh*

### Members:

*Jason Grebely*

*Maryam Alavi*

*Gregory Dore*

*Seyed Moayed Alavian*

*Afarin Rahimi-Movaghar*

---

## HA8 The Era of New Hepatitis C DAAs; From West to East

14:00-15:30

### Titles and Speakers:

- Western Real-life Experiences in the Treatment of HCV with DAAs

*Massimo Colombo (Italy), 45 min*

- IL 28B or IFNL4, The Basics of Host Genetics in HCV Infection

*Heidar Sharafi (Iran), 15 min*

- DAAs in Low-income Countries; Can We Personalize HCV Treatment?

*Seyed Moayed Alavian (Iran), 15 min*

- Discussion, 15 min

### Moderator:

*Seyed Moayed Alavian*

### Members:

*Massimo Colombo*

*Heidar Sharafi*

---

## HA9 From Probability to Certainty: Achieving Cure for All HCV Patients?

16:00-18:00

### Titles and Speakers:

- Estimating the Burden of Hepatitis C Virus Infection in Iran: How the Enhanced Antiviral Treatments Can Prevent The Rising Burden?

*Behzad Hajarizadeh (Australia), 15 min*

- Treating to Cure; Opportunity for Achieving SVR. What Does the Data Tell Us?

*Ashley Brown (UK), 60 min*

- What will it Take to Truly Cure HCV: a Call to Action

*Reza Malekzadeh (Iran), 20 min*

- Discussion, 25 min

### Moderator:

*Seyed Moayed Alavian*

### Members:

*Behzad Hajarizadeh*

*Ashley Brown*

*Reza Malekzadeh*

## ► Third Day, 29<sup>th</sup> May, 2015

## HA10 Hepatitis B in Liver Transplantation, OBI, and Pregnant Women with Hepatitis B

08:00-09:30

### Titles and Speakers:

- Hepatitis B Prophylaxis in Newborns

*Mario Rizzetto (Italy), 15 min*

- Iranian Experiences Regarding the HBV Prophylaxis in Newborns

*Seyed Moayed Alavian (Iran), 15 min*

- Clearance of HBV DNA in Immunized Children Born to HBsAg Positive Mothers, Years after Being Infected by Occult HBV Infection

*Seyed Mohamad Jazayeri (Iran), 15 min*

- The Management of Hepatitis B in Liver Transplantation

*Maria Rendina (Italy), 15 min*

## Scientific Program - Hall A

- Discussion, 15 min

**Moderator:**

*Seyed Moayed Alavian*

**Members:**

*Mario Rizzetto*

*Seyed Mohamad Jazayeri*

*Maria Rendina*

---

### HA11 Hepatology State of the Art Lectures, Third Day

10:00-10:45

**Titles and Speakers:**

- Autophagy, apoptosis and UPR, repercussions for HCV and HBV infection - introduction  
*Marek J. Los (Sweden), 20 min*
- Apoptosis, Autophagy, and Unfolded Protein Response in HCV and HBV Hepatitis  
*Behzad Yeganeh (Canada), 15 min*
- Q & A, 10 min

---

### HA12 Challenges in Viral Hepatitis; From Diagnosis to Management

10:45-12:15

**Titles and Speakers:**

- O145 Phylodynamic Reconstruction of Hepatitis B Virus D1, D2 and D3 Strains in Iran,  
*Mahmoud Reza Pourkarim (Belgium), 15 min*
- Challenges in Characterization of Immune Response and Development of New Therapies to Hepatitis Delta Infection  
*Hadi Karimzadeh (Germany), 15 min*

- O080 Viral Hepatitis: Using Social Sciences to Reduce the Burden

*Jack Wallace (Australia), 15 min*

- Reemergence of HEV: Should we be Concerned?

*F. Blaine Hollinger (USA), 25 min*

- HBV: Current Standards and Future Directions

*Robert Gish (USA)-video-conference, 20 min*

**Moderator:**

*Mahmoud Reza Pourkarim*

**Members:**

*Hadi Karimzadeh*

*Jack Wallace*

*Hosein Keyvani*

*F. Blaine Hollinger*

---

### HA13 Standard of the Care for Patients with Hepatitis C in 2015

13:30-15:00

**Titles and Speakers:**

- Molecular Diagnostics of Hepatitis C Virus Infection: Past, Present and the Future!  
*Siamak Tonekaboni (UK), 15 min*
- An Interferon-Free World for Hepatitis C: Moving the Agenda Forward  
*Gregory Dore (Australia), 20 min*
- Monitoring HCV Patients, on and off the Treatment  
*Peter Ferenci (Austria), 20 min*
- Are Special Patients Still Special?  
*Hatef Massoumi (USA), 20 min*
- Discussion, 10 min

**Moderator:**

*Hatef Massoumi*

**Members:**

*Peter Ferenci*

*Gregory Dore*

*Siamak Tonekaboni*

## Scientific Program - Hall B

► **First Day, 27<sup>th</sup> May, 2015**

### **HB1 Viral Hepatitis for Nurses-Hemodialysis**

08:00-9:50

#### **Titles and Speakers:**

- Welcome Ceremony, 15min
- Challenges in Hemodialysis, Peritoneal Dialysis and Viral Hepatitis  
*Afsaneh Jahanmardi (Iran), 20 min*
- Redesigning Orem's Self-Care Theory for Iranian Patients with Chronic Hepatitis B and C  
*Nouraldin Mohamadi (Iran), 20 min*
- Nursing Surveillance Guidelines around Patients Who Infected With Hepatitis B and C  
*Fatemeh Teimouri (Iran), 20 min*
- Hepatitis B and Hepatitis C in Hemodialysis Patients and Nursing Surveillance  
*Seyyed Jalil Hoseini (Iran), 20 min*
- Discussion, 15 min

#### **Moderator:**

*Aboalfazl Jaryani*

#### **Members:**

*Afsaneh Jahanmardi  
Nouraldin Mohamadi  
Fatemeh Teimouri  
Seyyed Jalil Hoseini  
Rosita Stami  
Farhad Kord  
Ali Azar Pasand  
Ali Akbar Shamsi*

### **HB2 Viral Hepatitis for Nurses-Prevention**

11:20-13:10

#### **Titles and Speakers:**

- Prevention and Control of Hepatitis B and C  
*Leila Azimi (Iran), 15 min*

- Different Models of Training to Patients with Hepatitis B and C

*Massoume Shishegaran (Iran), 15 min*

- Mental Health Problems of Nurses with Hepatitis B through Needle Stick

*Mohamad Imam Gholizadeh (Iran), 15 min*

- O156 Factors Associated With Preventive Behaviors of Hepatitis B among High School Girls Using the Health Belief Model

*Sedigheh Sameti (Iran), 15 min*

- Animation Show, 35 min

- Discussion, 15 min

#### **Moderator:**

*Aboalfazl Jaryani*

#### **Members:**

*Leila Azimi  
Massoume Shishegaran  
Mohamad Imam Gholizadeh  
Mahdi Zehbi  
Shokoah Nasri  
Hadi Saadat Manesh  
Hatam Ahmadvand*

### **HB3 Economics Burden of Liver Diseases**

14:00-15:50

#### **Titles and Speakers:**

- How to Approach to a Burden of Disease like Liver Dysfunction?

*Gholamhossein Mehralian (Iran), 20 min*

- Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?

*Mohamad Amin Pourhosein Gholi (Iran), 20 min*

- Economic Evaluation of Hepatitis Treatments and the Methods of Cost Reduction

*Shahram Tofighi (Iran), 20 min*

## Scientific Program - Hall B

- O062 Economic Burden of Hepatitis B Virus Related Diseases: Evidence from Iran

*Shekoufeh Nikfar (Iran), 15 min*

- O129 A Cost-Utility Analysis of Different Oral Antiviral Medications in Patients with Chronic Hepatitis B in Iran: A Micro-Simulation Economic Decision Model

*Khosro Keshavarz (Iran), 15 min*

- Discussion, 20 min

### Moderator:

*Mohamad Amin Pourhosein Gholi*

### Members:

*Gholamhossein Mehralian*

*Shahram Tofighi*

*Shekoufeh Nikfar*

---

## HB4 Epidemiology and Natural History of Viral Hepatitis

16:20-18:20

### Titles and Speakers:

- O076 Seroprevalence and Risk Factors of Hepatitis B Virus Infection in Birjand, Iran: A Population-based Study

*Masoud Ziaee (Iran), 15 min*

- O114 Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The Inc3 Study

*Behzad Hajarizadeh (Australia), 15 min*

- O118 Time to Seroconversion of HBsAg to Anti-HBs in Those Who Lost HBsAg during Follow-Up

*Mohammad Reza Hasanjani Roushan (Iran), 15 min*

- O133 Prevalence of Chronic HB Infection in Children and Spouses of Infected Individuals: A Prospective Cohort Study in Golestan Province

*Hosein Poustchi (Iran), 15 min*

- O219 Epidemiology of Hepatitis C Virus Infection among Drug Users in Iran: A Meta-analysis

*Ali Kabir (Iran), 15 min*

- O233 Spontaneous Loss of HBsAg in Chronic Hepatitis B Infected Individuals and Their Children: A Large Population-based Prospective Cohort Study in Golestan

*Aezam Katoonizadeh (Iran), 15 min*

- O270 The Intrafamilial Prevalence of Hepatitis C Virus Infection among Families with One Index Case, A Study From South of Iran

*Seyed Younes Hosseini (Iran), 15 min*

- Discussion, 15 min

### Moderator:

*Peyman Adibi*

### Members:

*Mohammad Reza Hasanjani Roushan*

*Hosein Poustchi*

## ► Second Day, 28<sup>th</sup> May, 2015

## HB5 Practical Guideline & Novel Therapeutic Approach to Chronic HBV

08:00-10:00

### Titles and Speakers:

- Dendritic Cell Vaccine in Treatment of Viral Hepatitis

*Mostafa Alavi-Moghadam (Iran), 20 min*

- Treatment of Chronic HBV for Special Population (Cirrhosis, Chemotherapy, Immune Suppressive, HIV Co-infection)

*Shervin Shokoohi (Iran), 20 min*

- Treatment Goals, Optimal First Line and End Point Treatment of Chronic HBV

*Shahnaz Sali (Iran), 20 min*

- Prevention and Monitoring of Drug-Resistance of Chronic HBV,

*Masoud Mardani (Iran), 20 min*

## Scientific Program - Hall B

- On-Treatment Monitoring and Response Evaluations in Chronic HBV

*Davood Yadegarynia (Iran), 20 min*

- Discussion, 20 min

### Moderator:

*Shahnaz Sali*

### Members:

*Mostafa Alavi-Moghadam*

*Shervin Shokoohi*

*Masoud Mardani*

*Davood Yadegarynia*

*Hosein Foroutan*

---

## HB6 Viral Hepatitis-Basic Studies

11:30-13:00

### Titles and Speakers:

- O086 Inverse Association of Glutathione Peroxidase with Liver Fibrosis in Chronic Hepatitis B

*Ashraf Mohamadkhani (Iran), 15 min*

- O281 Introducing a Mathematical Algorithm for Predicting Viral Load in HBV Infected Subjects Using Surrogate Markers

*Hiva Sharebiani (Iran), 15 min*

- O282 Diagnosis of Hepatitis Disease Using Fuzzy K Nearest Neighbor Approach

*Bitan Baran (Iran), 15 min*

- O257 Transfection of Insect Cells (SF9) by ReR combinant Baculovirus Containing HCV Core+1 of Genotype 1JFH1

*Farideh Sadat Sajadian Fard (Iran), 15 min*

- O162 The Effects of Hepatitis C Virus NS3 Protein on the Expression of miR-122 and Fibrogenesis of Hepatic Stalled Cells in vitro

*Sayyad Khanizadeh (Iran), 15 min*

- Discussion, 15 min

### Moderator:

*Ashraf Mohamadkhani*

### Members:

*Hadi Karimzadeh*

---

## HB7 Noninvasive Methods of Diagnosing Hepatic Fibrosis

14:00-15:30

### Titles and Speakers:

- Can We Replace Liver Biopsy with Non-invasive Procedures?

*Eskandar Hajiani (Iran), 15 min*

- Clinical Application of Elastography Imaging in Liver Fibrosis

*Hosein Poustchi (Iran), 15 min*

- Fibrosis Tests and Serum Biomarkers

*Mohsen Nasiri-Toosi (Iran), 15 min*

- Novel Imaging Technologies of Liver Fibrosis in Clinical Practice

*Iraj Maleki (Iran), 15 min*

- O228 Non-invasive Serum Fibrosis Markers: A Study in Chronic Hepatitis

*Mohammadreza Abdollahi (Iran), 10 min*

- Case Presentation and Panel Discussion, 20 min

### Moderator:

*Eskandar Hajiani*

### Members:

*Hosein Poustchi*

*Mohsen Nasiri-Toosi*

*Iraj Maleki*

*Farhad Zamani*

---

## HB8 Autoimmune Hepatitis-Postgraduate Course

16:00-18:00

### Titles and Speakers:

- Epidemiology of Autoimmune Hepatitis in Iran and World

*Mohammad Hosein Somi (Iran), 15 min*

## Scientific Program - Hall B

- Clinical Manifestations of Hepatic and Extra Hepatic Disease in Autoimmune Hepatitis

*Mohamad reza Ghadir (Iran), 15 min*

- Pathogenesis of Autoimmune Hepatitis

*Mostafa Alavi-moghadam (Iran), 15 min*

- Diagnosis of Autoimmune Hepatitis

*Mehdi Shekarabi (Iran), 15 min*

- Treatment of Autoimmune Hepatitis

*Ahmad Shavakhi (Iran), 15 min*

- Resistance to Treatment of Autoimmune Hepatitis

*Mohsen Masoodi (Iran), 15 min*

- O208 Autoimmune Hepatitis and Apoptosis, Autophagy, Unfolded Protein Response

*Behzad Yeganeh (Canada), 15 min*

- Discussion, 15 min

### **Moderator:**

*Mohammad Hosein Somi*

### **Panel Members:**

*Mohamad reza Ghadir*

*Ahmad Shavakhi*

*Mohsen Masoodi*

*Sepideh Haghazali*

## ▶ Third Day, 29<sup>th</sup> May, 2015

### **HB9 Challenges in Host Genetics, Diagnosis and Treatment in HIV/HCV Co-infected Patients: Consideration to Developing Vaccine**

08:00-09:30

#### **Titles and Speakers:**

- Antiretroviral Therapy in Patients with HIV/HCV Co-infection

*Mohammad Reza Hasanjani Roushan (Iran), 15 min*

- Diagnosis of HCV Infection in HIV/HCV Co-infected Patients

*Mahdi Paryan (Iran), 10 min*

- Role of Cytokines Genes Polymorphisms in ReR sponse to Therapy in Patients with Hepatitis C Infection

*Seyed Mehdi Sadat (Iran), 15 min*

- Role and Function of Hepatitis C virus Core +1 Protein

*Pouneh Rahimi (Iran), 10 min*

- Challenge for HCV Vaccine Development in HIV/HCV Co-infection

*Azam Bolhasani (Iran), 15 min*

- O267 Torque TenoVirus Infection Frequency in Iranian HIV/HCV Coinfected Patients and Comparison with Chronic Hepatitis C Virus Mono Infection and Healthy Control

*Hosna Rastegarpouyani (Iran), 10 min*

- Discussion, 15 min

### **Moderator:**

*Mohammad Reza Aghasadeghi*

### **Members:**

*Mohammad Reza Hasanjani Roushan*

*Seyed Mehdi Sadat*

*Azam Bolhasani*

*Minoo Mohraz*

*Mehri Nikbin*

### **HB10 Hepatocellular Carcinoma: Update**

10:45-12:15

#### **Titles and Speakers:**

- Molecular Epidemiology of Hepatocellular Carcinoma: Common Ground and Local Differences

*Pascal Pineau (France), 15 min*

- Targeted Therapy for Hepatocellular Carcinoma

*Amir Hosein Emami (Iran), 15 min*

- Endosonography for Liver and Pancreatic Disi

## Scientific Program - Hall B

eases

*Siavosh Mansouri (Iran), 10 min*

- Transarterial Chemoembolization in Hepatocellular Carcinoma

*Hosein Ghanaati (Iran), 15 min*

- O098 Time to Hepatocellular Carcinoma Diagnosis after Notification of Hepatitis B or C Infection: a Population-based Cohort Study, 1992 to 2006

*Maryam Alavi (Australia), 10 min*

- O140 The Incidence Rate of Hepatocellular Carcinoma in Patients with Cirrhosis and Offering a Decision Support System for Early Cancer Prediction

*Melina Ebrahimi (Iran), 10 min*

- Discussion, 15 min

### **Moderator:**

*Hosein Ghanaati*

### **Panel Members:**

*Pascal Pineau*

*Amir Hosein Emami*

*Siavosh Mansouri*

*Mahdi Saberi Firouzi*

---

## **HB11 Strategic Programs of Viral Hepatitis Control in Iran**

13:30-15:00

### **Titles and Speakers:**

- Strategic Programs of Viral Hepatitis Control

*Alireza Shoghli (Iran), 20 min*

- Studies and Reports of HBV Epidemiology in Iranian High Risk Groups

*Mojtaba Fallahnezhad (Iran), 20 min*

- Studies and Reports of HBV Epidemiology in Iranian Pregnant Women

*Nima Motamed (Iran), 20 min*

- Report of Viral Hepatitis Infections to Iranian Health Ministry

*Mahmood Nabavi (Iran), 20 min*

- Discussion, 10 min

### **Moderator:**

*Alireza Shoghli*

### **Members:**

*Mojtaba Fallahnezhad*

*Nima Motamed*

*Mahmood Nabavi*

*Shahram Agah*

*Babak Sayad*



## Scientific Program - Hall C

► **First Day, 27<sup>th</sup> May, 2015**

### **HC1** Viral Hepatitis in People Who Inject Drug

08:00-09:50

#### **Titles and Speakers:**

- Addiction and Viral Hepatitis  
*Parviz Afshar (Iran), 25 min*
- O265 HBsAg & HCVAb Prevalence among Female Sex Workers Referred To DICs and VCTs in Selected Capital Cities, Iran  
*Mojtaba Fallahnezhad (Iran), 15 min*
- O280 Hepatitis B and Hepatitis C Seroprevalence among Injecting Drug Users Referred To DICs and VCTs in Selected Capital Cities, Iran  
*Seyed Mahmood Nabavi (Iran), 15 min*
- O193 HCV Prevalence Can Predict HIV Epidemic Potential among People Who Inject Drugs: Preliminary Results  
*Vajiheh Akbarzadeh (Qatar), 15 min*
- Discussion, 15 min

#### **Moderator:**

*Parviz Afshar*

#### **Members:**

*Behrooz Ataei  
Alireza Shoghli  
Vajiheh Akbarzadeh*

### **HC2** Occult Viral Hepatitis

11:20-13:10

#### **Titles and Speakers:**

- O247 Occult Hepatitis B Virus Infection in HIV Infected Patients of Iran  
*Sareh Zhand (Iran), 20 min*
- O261 Prevalence of Occult Hepatitis C Virus Infection in the Iranian Patients with Human Immunodeficiency Virus Infection  
*Farah Bokharaei Salim (Iran), 20 min*

- O274 Molecular Characterization and Functional Analysis of Hepatitis B Surface Gene in HIV Positive Patients with Occult Hepatitis B Infection  
*Ahmadreza Sadeghi (Iran), 20 min*

- Discussion, 30 min

#### **Moderator:**

*Seyed Mohamad Jazayeri*

#### **Members:**

*Zahra Ahmadinejad  
Farah Bokharaei Salim*

### **HC3** Viral Hepatitis & Host Genetics

14:00-15:50

#### **Titles and Speakers:**

- O117 Relation between Interleukin-12 Receptor B1 Gene Polymorphism (rs3746190 A/G) and Chronic Hepatitis B Virus Infection Susceptibility  
*Mojtaba Salehi (Iran), 15 min*
- O136 Study of Effect of ITPA Gene Polymorphisms on Pegylated Interferon/Ribavirin-induced Anemia and Sustained Virologic Response in Iranian Patients with Chronic Hepatitis C Infection  
*Mohammad Pouryasir (Iran), 15 min*
- O173 Association of IL-28B Gene Polymorphism at rs12979860 T/C with Spontaneous Clearance of HCV Infection in Fars Province, South of Iran  
*Jamal Sarvari (Iran), 15 min*
- O213 Cytochrome P450 Gene (CYP2E1 and CYP1A1) Polymorphisms and Susceptibility to Chronic Hepatitis B Infection  
*Galia Amirbozorgi (Iran), 15 min*
- O307 The Role of Polymorphisms near IL28B Gene On Response To Peg-interferon and Ribavirin in Thalassaemic Patients with Hepatitis C  
*Bita Behnava (Iran), 15 min*
- Discussion, 35 min

#### **Moderator:**

*Jamal Sarvari*

## Scientific Program - Hall C

### Members:

*Afsaneh Sharifian*  
*Bitra Behnava*

---

### HC4 Update on HCV Vaccine

16:20-18:20

#### Titles and Speakers:

- O254 Evaluation of Immune Responses for a Recombinant HCV Core+1 Protein Formulated in Different Human Compatible Adjuvants- A Potential Immunotherapeutic for HCV Induced HCC?  
*Farzin Roohvand (Iran), 20 min*
- O268 Immunogenicity of HCV Multi-epitope DNA Vaccine and its Fusion to N-terminal Domain of Heat Shock Protein gp96 Construct in Mice Model  
*Leila Pishraft-Sabet (Iran), 20 min*
- O232 Canola (*Brassica napus*) Oilseeds and Extracts as Novel and Superior Tools in Formulation of a Plant-based HCV Vaccine Candidate  
*Sara Mohammadzadeh (Iran), 20 min*
- O253 Immune Responses to a CD8-CTL Epitope of HCV Core Protein (aa: 39-48) in the Context of a Synthetic Polytope and Native Protein-A Comparative Study  
*Maryam Yazdanian (Iran), 20 min*
- Discussion, 40 min

#### Moderator:

*Farzin Roohvand*

#### Members:

*Mahtab Shaabani*  
*Katayoon Samimi-rad*

► **Second Day, 28<sup>th</sup> May, 2015**

### HC5 Management of Hepatitis C

08:00-10:00

#### Titles and Speakers:

- O084 Pilot Clinical Trial with Chloroquine in Non-responding HCV Patients AND O099 Effect of Chloroquine Therapy on Anthropometric Parameters, Vit D3, Ferritin and Biochemistry Parameters at HCV Infection Patients: Pilot Trial  
*Payam Peymani (Iran), 25 min*
- O116 Efficacy of Response-guided Pegylated Interferon and Ribavirin Therapy for People who Inject Drugs with HCV Genotype 2/3 Infection: the ACTIVATE Study  
*Jason Grebely (Australia), 20 min*
- O260 Outcome of Patients with Hepatitis C in Gilan Province from 1381 to the End of 1391  
*Fariborz Mansour-Ghanaei (Iran), 20 min*
- O277 High Response Rate to Pegylated Interferon on Alpha and Ribavirin Combination Therapy in Haemophilic Children with Chronic Hepatitis C; A Case-Control Study  
*Bitra Behnava (Iran), 20 min*
- Discussion, 35 min

#### Moderator:

*Rahim Aghazadeh*

#### Members:

*Jason Grebely*  
*Fariborz Mansour-Ghanaei*  
*Mehrdad Haghazali*  
*Bitra Behnava*

---

### HC6 Viral Hepatitis-Molecular Studies

14:00-15:30

#### Titles and Speakers:

- O110 Phylogenetic Evidence of Intrafamilial Transmission of Hepatitis B Virus among Household Members with Chronic Infection  
*Maryam Vaezjalali (Iran), 15 min*
- HBV Genotyping and Subgenotyping Misclassification  
*Mahmoudreza Pourkarim (Belgium), 20 min*

## Scientific Program - Hall C

- O288 Hepatitis B Virus; Genotyping and Mutation Pattern of S/RT Gene in HBV Isolates of Birjand

*Davoud Javanmard (Iran), 15 min*

- O149 Hepatitis D virus Promotes Inhibitory Effects on Replication of Hepatitis B Virus Isolates Containing Precore and Basal Core Promoter Mutations

*Elham Shirvani-Dastgerdi (Germany), 20 min*

- Discussion, 20 min

### **Moderator:**

*Maryam Vaezjalali*

### **Members:**

*Mohamadreza Aghasadeghi*

*Seyed Reza Mohebbi*

*Mahmoudreza Pourkarim*

---

## **HC7 Liver Diseases in Middle Eastern and Central Asian Countries**

16:00-18:00

### **Titles and Speakers:**

- O068 Hepatitis C Genotypes/subtypes among Chronic Hepatitis C Patients in Iraq

*Akram Ajeel Najeeb (Iraq), 15 min*

- O073 Hepatitis B, C, and D Viruses in Tajikistan

*Saodta Azimova (Tajikistan), 15 min*

- O075 A Study on Clinical & Serological Markers of Chronic HBV Infection in Babylon

*Monem Makki Alshok (Iraq), 15 min*

- O194 Protocol for a Systematic Review and Meta-analysis of Hepatitis C Virus (HCV) Prevalence and Incidence in the Horn of Africa Sub-region of the Middle East and North Africa

*Karima Chaabna (Qatar), 15 min*

- O302 Epidemiological Characteristics of Acute Symptomatic Hepatitis A in Al Alwyia Pediatric Teaching Hospital During 2013

*Tareef Fadhil Raham (Iraq), 15 min*

- NAFLD "Risk Stratification Module" Project

*Azzam Kayasseh (UAE), 15 min*

- O308 Hepatitis E Virus in Patients with HIV Infection

*Abdusamad Dustov (Tajikistan), 15 min*

- Discussion, 30 min

### **Moderator:**

*Masoud Salehi*

### **Members:**

*Akram Ajeel Najeeb*

*Saodta Azimova*

*Karima Chaabna*

*Seyed Hamid Mousavi*

## **► Third Day, 29<sup>th</sup> May, 2015**

## **HC8 Viral Hepatitis and Blood Safety**

08:00-09:30

### **Titles and Speakers:**

- Look Back and Blood Safety

*Sedigheh Amini (Iran), 15 min*

- Donor Selection and Blood Safety

*Mahtab Maghsoodlu (Iran), 15 min*

- Haemovigilance

*Sima Zolfaghari (Iran), 15 min*

- O146 Blood Safety and Thalassemia Major PaP tients

*Ali Davoudi-kiakalayeh (Iran), 15 min*

- O278 Prevalence and Trends of Transfusion-transmitted Infections among Blood Donors in Tehran, Iran from 2008 to 2013

*Heidar Sharafi (Iran), 15 min*

- Discussion, 15 min

### **Moderator:**

*Sima Zolfaghari*

### **Members:**

*Sedigheh Amini*

*Mahtab Maghsoodlu*

*Maryam Zadsar*

*Ali Akbar Pourfatollah*

## Scientific Program - Hall C

### HC9 An Approach toward Non-alcoholic Fatty Liver Disease (NAFLD)

10:45-12:15

#### Titles and Speakers:

- Fatty Liver and Metabolic Syndrome  
*Raika Jamali (Iran), 15 min*
- Epidemiology of Fatty Liver Disease in Iran and World  
*Mohamad Jafar Farahvash (Iran), 15 min*
- Diagnosis of Fatty Liver Disease  
*Ahmad Sadeghi (Iran), 15 min*
- Management of Fatty Liver Disease  
*Amir Ali Sohrabpour (Iran), 15 min*
- O064 Evaluation of L-Carnitine Efficacy in the Treatment of Non-alcoholic Fatty Liver Disease among Diabetic Patients: A Randomized Pilot Study  
*Pezhman Alavinejad (Iran), 15 min*
- Discussion, 15 min

#### Moderator:

*Raika Jamali*

#### Members:

*Mohamad Jafar Farahvash  
Ahmad Sadeghi  
Amir Ali Sohrabpour  
Akram Pourshams  
Faramarz Derakhshan  
Bahram Seifi-zarei*

### HC10 The Role of Education in Prevention and Control of Liver Diseases

14:00-16:00

#### Titles and Speakers:

- Hepatitis B and Hepatitis C: Past, Present and Future  
*Seyed Moayed Alavian*
- The Role of Non-governmental Organizations in Support of the Hemophilia Patients  
*Ahmad Ghavidel*
- Thalassemia and Hepatitis  
*Mohamad Reza Mashhadi*
- The Use of New Tools in Public Education (Introduction of OMID Software)  
*Kamal Moghadam*
- The Role of Municipalities in Public Health (Challenges in Fatty Liver, Exercise and Health)  
*Davoud Amiri*

## Scientific Program - Additional Day (Shiraz)

### **S1** General Discussion on Hepatitis

08:30-10:30

#### **Titles and Speakers:**

- Opening and Status of Hepatitis in Iran and the World  
*Mohammad Hadi Imanieh (Iran), 15 min*
- National Hepatitis Program  
*Seyed Mahdi Gooya (Iran), 15 min*
- Surveillance of HBS-Ag Positive Patients  
*Mohammad Reza Fattahi (Iran), 15 min*
- Surveillance of HCV-Ab Positive Patients  
*Kamran Bagheri Lankarani (Iran), 15 min*
- Evaluation of Patients with Impaired Liver Function Test  
*Seyed Alireza Taghavi (Iran), 15 min*
- Hepatitis A in Pediatrics  
*Seyed Masoud Haghghat (Iran), 15 min*
- Hepatitis A in Adults  
*Behnam Honarvar (Iran), 15 min*
- Symptoms of Liver Damage in Non-viral Hepatitis Infections  
*Mohsen Moghadami (Iran), 15 min*

### **S2** Liver Transplantation and Hepatocellular Carcinoma

11:00-13:00

#### **Titles and Speakers:**

- Liver Transplantation in Iran  
*Seyed Ali Malekhosseini (Iran), 20 min*
- Biology and Prophylaxis of HDV Infection in Liver Transplants  
*Mario Rizetto (Italy), 20 min*
- Treatment of Hepatitis C Recurrence after Liver Transplantation-Indications and Outcomes  
*Bijan Eghtesad (USA), 20 min*
- Management of Hepatitis B Patients in Liver Transplantation  
*Maria Rendina (Iran), 20 min*
- Burden of Liver Cancer in Iran  
*Seyed Moayed Alavian (Iran), 20 min*
- Circulating Nucleic-acid Based Markers in Hepatocellular Carcinoma  
*Pascal Pineau (France), 15 min*

# THC6 Workshops

## **W1 How to Write a Scientific Paper**

*By Mario Mendelli, 27<sup>th</sup> May, 08:00-09:30 in Hall D*

## **W2 How to Design a Basic Science Project**

*By Frank Tacke and Elham Shirvani-Dastgerdi, 27<sup>th</sup> May, 11:20-13:10 in Hall D*

### **Program:**

1. How to Design a Basic Science Project – Frank Tacke, Aachen, Germany
2. Carrying out scientific projects in western universities - the student's point of view – Elham Shirvani-Dastgerdi, Aachen, Germany / Tehran, Iran
3. Project proposals: Q & A – participants are invited to present their ideas or concepts on basic science projects!

### **Objective:**

Design is the most fundamental part of any project which determines its directions and organizes the aims of the research. The methods that you choose to conduct your experiments and the analytical methods that you apply to conclude your data, are of great importance. Brain storming and exchanging the ideas, scheming the experiments, analyzing the results and publishing your findings are all necessary steps in a project design.

## **W3 How to Design a Clinical Trial**

*By Peter Ferenci, 27<sup>th</sup> May, 14:00-15:30 in Hall D*

## **W4 Meta-Analysis**

*By Mohammad Gholami Fesharaki, 28<sup>th</sup> May, 11:30-13:00 in Hall D*

## **W5 Meta-Analysis**

*By Ali Kabir, 28<sup>th</sup> May, 14:00-15:30 in Hall D*

## **W6 The Use of Social Media in Medicine**

*By Mohammad Sajjad Rahnama 'I, 29<sup>th</sup> May, 10:45-12:15 in Hall D*

In this workshop, a general introduction of the most widely used social media (such as LinkedIn, Facebook and Twitter) will be discussed, followed by the use of these applications in the field of medicine. Through examples, the proper use and the advantage of using social media in medical practice will be discussed, as well as the dangers and the disadvantages. Finally, tips and tricks will be exchanged to set up a useful profile and get connected to relevant people in your line of medical interest and research.

## Poster Presentations-Young Investigators Section-27<sup>th</sup> May, 10:00-14:00

P067 Natural History Of Chronic Hbv Infection: A Cohort Study With Up To 11 Years Follow-Up In Birjand Hepatitis Clinic, In East Of Iran, By *Tahereh Darvishpour Kakhki*

P085 Health Literacy Disparities About Hepatitis B:a National Assessment In Iran, By *Kiandokht Bashiri*

P093 Detection Residual Host Cell Dna By Polymerase Chain Reaction Technique In Recombinant Hepatitis B Vaccine, By *Mahdi Paryan*

P094 Hepatitis A Seropositivity Among Newly Admitted Medical Students Of Isfahan, Kermanshah, And Hamedan: A Seroprevalence Study, By *Parisa Shoaee*

P101 Curcumin: A Promising Natural Chemotherapeutic Agent In Treating Hepatocellular Carcinoma, By *Mahsa Motavaf*

P112 Bioinformatics Analysis In Polymerase Gene Of Hepatitis B Virus Isolated From Iranian Patients, By *Ali Namvar*

P122 Evaluation Of Adding Vitamin D To Standard Hcv Regimen (Peg-Interferon Plus Ribavirin) On Early Virologic Response (Evr), By *Ladan Goshayeshi*

P135 Snapshot On Drug-Resistance Rate In Nucleos (T)ide Analogue- Naïve And-Treated Patients With Chronic Hepatitis B In Clinical Practice, By *Fatemeh Bakhshizadeh*

P138 Fatty Acids In Cerebrospinal Fluid Is Correlated With Liver Enzymes Tests, By *Sepideh Ghodoo-sifar*

P141 Disaster In Hiv Patients: Seven Cases With Quadruple Deadly Co-Infection, Shiraz, Iran, By *Shahab Mahmoudvand*

P151 Pcd1 Genetic Diversity At Position +7785 Has Not Shown Correlation With Hcv Infection, By *Razieh Dowran*

P153 Non-Alcoholic Fatty Liver Disease And Obesity In Children: Review Article, By *Sina Dindarian*

P159 Interleukin-10 Promoter Polymorphism -1082 A/G (Rs1800896) In Patients With Hepatitis B Virus Infection, By *Farzaneh Sadat Mirfakhar*

P161 Effect Of Donor Age On The Result Of Liver Transplantation: Review Article, By *Mahdi Bagheri*

P163 Evaluation Of High Oxygen Saturation In Cirrhotic Patients, By *Ali Adib*

P164 Risk Factors Of Hcv Transmission Among Patients In Motahari Hepatitis Clinic Of Shiraz On 2014-2015; A Cross Sectional Study, By *Amir Hossein Babaei*

P165 Risk Factors And Demographic Features Of Hbv Infection In Patients Referred To Motahari Hepatitis Clinic Of Shiraz 2014-2015, By *Moeinodin Abedinirad*

P168 Outcome Of Accidental Exposure Prone To Blood Borne Viral Infections In An Educational Hospital, 6 Years Follow Up, By *Shabnam Tehrani*

- P169 Evaluation Of Interleukin-27 Gene Polymorphism (2905 T/G) In Patients With Chronic Hepatitis C Virus Infection, By *Samira Mokhtari*
- P176 Seven Years Trends In Prevalence Of Major Transfusion-Transmissible Viral Infections In Shiraz Blood Transfusion Organization, By *Leila Kasraian*
- P178 The Pre-S2 Sequence Mutations Associated With Hbv Disease Consequence Among Different Patients Groups, By *Mohammad Taghiabadi*
- P180 The Survey Of Pre-S1 Sequence Mutations Among Different Hbv Infected Groups, Possible Association With Disease Consequence, By *Mohammad Taghiabadi*
- P184 The Dominant Prevalence Of Genotype D Among Different Hbv Infected Patient Groups, A Study From Referral Center In South Of Iran, By *Mohammad Taghiabadi*
- P190 Willingness To Receive Treatment For Hepatitis C Virus Among Drug Injectors On Methadone Program: Implications For Hcv Knowledge And Education, By *Zahra Alam-Mehrjerdi*
- P192 Shared Methamphetamine Injection Among Treatment Seekers And Positive Hepatitis C Status: The First Report From Persian Iran, By *Zahra Alam-Mehrjerdi*
- P211 Interleukin-28B (Rs12979860) Gene Variation And Treatment Outcome After Peginterferon Plus Ribavirin Therapy In Patients With Genotype 1 Of Hepatitis C Virus, By *Tahmine Tavakoli*
- P215 The Effects Of Single Nucleotide Polymorphism Of Il28b Gene (Rs12980275) On Treatment Response To Pegylated Interferon/Ribavirin In Iranian Patients With Hepatitis C, By *Mahsa Zamanian*
- P217 Association Of Il28b Gene (Rs8099917) Polymorphism With Treatment Response In Chronic Hepatitis C Patients Treated With Pegylated Interferon/Ribavirin In Iran, By *Mahsa Zamanian*
- P220 Seroprevalence Study Of Hepatitis B Virus Among Hospitalized Intravenous Drug Users In Tehran, Iran (2012-2013), By *Tahmineh Kandelouei*
- P221 Vertical Hepatitis In A Five Year Period In Zabol Hospital, By *Aliyeh Sargazi*
- P229 Long Term Therapeutic Consequences In Patients With Autoimmune Hepatitis, By *Mohammadreza Abdollahi*
- P230 Evaluation Of Surveillance Systems For Hepatitis B In Iran, By *Seyed Hossein Hosseini*
- P242 Lack Of Association Between Il12a Single Nucleotide Polymorphism (Rs6887695g/C) And Chronic Hepatitis B Virus Infection, By *Sedigheh Heidarian*
- P250 Seroprevalence Of Hepatitis A And Hepatitis E Virus In Healthy Blood Donors From Tehran, Iran, By *Khashayar Hesamizadeh*
- P259 Cloning Of Hcv Core+1 Gene In Baculovirus Expression System, By *Fahimeh Safarnezhad Tameshkel*
- P286 Surveillance And Epidemiology Of Hepatitis B, C, D And G In Khuzestan Province, Southwest Iran- A Review, By *Amir Pouremamali*



P295 Comparative Study On The Chemical And Medicinal Effects Of Indigenous Silybum Marianum From Egypt And Medicinal Silymarin From China On The Treatment Of Liver Fibrosis On Female Albino Ra, *By Engy M.a. Elfetoh*

P303 Occult Hepatitis B Infection In Hepatitis C Patients With Haematological Disorders, *By Reza Ajudani*

P304 Seroprevalence Of Hepatitis A Virus Among Iranian Soldiers, *By Mohammad Saeid Rezaee-Zavareh*

P305 Are Women With Polycystic Ovarian Syndrome At A High Risk Of Non-Alcoholic Fatty Liver Disease; A Meta-Analysis, *By Mahdi Ramezani-Binabaj*

## Poster Presentations-28<sup>th</sup> May, 10:00-14:00

P063 The Effect Of Pentoxifylline On Liver Function Tests In Non-Alcoholic Fatty Liver Disease Non-Diabetic Patients, By *Raika Jamali*

P069 Helicobacter Pylori Seroprevalence In Iraqi Patients Infected With Hepatitis C Virus, By *Akram Ajeel Najeeb*

P070 Serological Profile Of Hbv Infection And The Associated Risk Factors Among Hiv Positive Individuals In Shiraz, Southern Iran, By *Nasrin Motazedian*

P072 Hepatitis E Virus Seroprevalence In Hiv Positive Individuals In Shiraz, Southern Iran, By *Omid Rudgari*

P074 Particularities Of The Course Of Chronic Hepatitis Of Mixed Viral Etiology (Hbv + Hcv), By *Saodat Azimova*

P077 Survey Of Serological And Virological Markers Of Hepatitis B In Patients Co-Infected With Both Hiv And Hepatitis C, By *Mohammad Mahdi Majzoobi*

P079 Changes Of Epidemiological Model Of Hepatitis In Ilam Province Between 2009-2012, By *Khadijeh Javaheri*

P083 Viral Load Changes In Hepatitis C Patients With Different Genotypes, Golestan Province, By *Sima Besharat*

P088 Prevalence And Risk Factors Of Hepatitis C Infection In Birjand, By *Azadeh Ebrahimzadeh*

P091 Prevalence Of Hcv Genotypes Among Prisoner Patients With Chronic Hepatitis C Infection In South Khorasan Prisons-2014, By *Zohreh Azarkar*

P092 Association Of The Hepatic Sortilin With Reduced Level Of Hepatic Hbsag In Chronic Hepatitis B Patients, By *Ashraf Mohamadkhani*

P095 A Survey Of The Prevalence Of Depression In Blood Donors With Hepatitis C In Shiraz, By *Leila Kasraian*

P096 Influencing Factors On Sustain Virological Response Through Peg & Ribavirin In Chronic Hepatitis C Virus, By *Shahnaz Sali*

P097 Occult Hepatitis B Virus Infection Among Human Immunodeficiency Virus-Infected Patients With Isolated Hepatitis B Core Antibody In Isfahan, Iran, By *Parisa Shoaei*

P100 Non-Invasive Histologic Markers Of Liver Disease In Patients With Chronic Hepatitis B, By *Shahnaz Sali*

P102 Effects Of Oral Levamisole As An Adjuvant To Hepatitis B Vaccine In Health Care Workers Non Responder To Previous Vaccinations: A Randomized Controlled Trial, By *Babak Sayad*

P104 The Therapeutic Use Of Analgesics In Patients With Liver Cirrhosis: A Literature Review And Evidence-Based Recommendations, By *Mahsa Motavaf*

P105 Hepatotoxicity Of Halogenated Inhalational Anesthetics, By *Mahsa Motavaf*

- P107 Comparative Study Of Health Related Quality Of Life In Patients With Hepatitis C And Healthy People And Present A Structural Model, By *Maryam Momeni*
- P115 Determination Of Genotype And Viralload Of Hcv Among Thalassemic Patient Suffering Hepatitis, By *Vahid Babaei*
- P119 Molecular Genotyping Of Hepatitis C Virus In The General Population In Iran, By *Maryam Karkhane*
- P120 Hepatitis B Vaccination Coverage Among Dentists In Iran: A Systematic Review And Meta-Analysis Study, By *Milad Azami*
- P123 Prevalence Of Hepatitis B Surface Antigenpositive In Pregnant Women Referred To Beheshti Hospital Of Kashan -Isfahan, 2012, By *Hasan Afzali*
- P124 Epidemiological Distribution, And Genotype Characterization Of Hepatitis C Virus Among Hiv Patients In Kashan-Iran, By *Mansooreh Momen-Heravi*
- P125 Prevalence Of Hepatitis C In Intravenous Drug Abusers In Kashan, By *Mansooreh Momen-Heravi*
- P126 Prevalence Of Infectious Disease In Liver Transplant Patients In Imam Khomeini Hospital Tehran-Iran, By *Alireza Sharif*
- P127 The Frequency Of Infection Of Hbv, Hcv And Hiv In Idu, By *Zarichehr Vakili*
- P143 A Review In Dental Management In Viral Hepatitis, By *Arghavan Tonkaboni*
- P144 An Integrated Map Of Hbv Genome-Wide Variation From The World Population Perspective, By *Mahmoudreza Pourkarim*
- P147 A Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction For Genotyping Of Rs8099917 & Rs12979860 Il28b Polymorphisms In Iranian Hcv Patients, By *Tahereh Fakharian*
- P150 No Association Of Genetic Variation At Pd1.5 Loci With Spontaneously Clearance Of Hcv Infection, By *Jamal Sarvari*
- P154 Seroprevalence Of Hepatitis B Among Pregnant Women In Iran, By *Farhad Abbasi*
- P155 Evaluation Of The Frequency Of Hepatitis B And Hepatitis C In Major Thalassemic Patients In Bushehr, Iran, By *Farhad Abbasi*
- P158 Liver Histopathologic Changes In Hbeag Negative, Normal Alt Chronic Hepatitis B Patients And Correlation With Viral Load, By *Elmira Ghoujehi*
- P167 Mutual Effects Of Hcmv Infection And Immune System In Liver Failures, By *Faezeh Maleki*
- P170 Prevalence Of Hepatitis B Genotypes In Patients With Hepatitis B In Lorestan Province (2010-2014), By *Mohamadreza Nazer*
- P171 Chronic Hcv Infection And Stroke: A Review, By *Zia Obeidavi*
- P172 No Association Of Il-28B Gene Polymorphism At Rs8099917 T/G With Hcv Infection Outcome In Fars

Province, South Of Iran: Spontaneous Clearance Versus Chronic Infection, *Jamal Sarvari*

P174 A Survey Of Transfusion Requirements In Liver Transplantation, By *Leila Kasraian*

P177 Relationship Between Hepatitis B Virus Dna Load In The Liver And Liver Histology In Patient With Chronic Hepatitis B, By *Tahmineh Biazar*

P179 Assessment Of Hcv Genotype In Iv Drug Abuser In Mashhad 2011-2013, By *Real Time Per* , With Taq Man Method, By *Farshid Abedi*

P185 Stigma Outcomes In Patients With Hepatitis C, By *Maryam Momeni*

## Poster Presentations-29<sup>th</sup> May, 10:00-14:00

P186 Assess Of Knowledge And Attitudes From Military Personnel In The Prevention Of Drug Abuse, By *Zeinab Tabanejad*

P201 Molecular Prevalence Of Transfusion Transmitted Virus In Beta Thalassemia Children, By *Abdolreza Sotoodeh*

P202 Clinical Importance Of Tt Virus Infection In Haemodialysis Patients, South Of Iran, By *Abdolreza Sotoodeh*

P203 Hepatitis B Virus Genotypes In South Of Iran, By *Abdolreza Sotoodeh*

P206 How Nurses Who Are Occupationally Exposed To Hcv Infection Can Help To The Difficult-To-Treat Hepatitis C Population?, By *Nader Aghakhani*

P210 Study On The Presence Of Hcv Rna In Thalassemic Patients With Hepatitis C After Treatment, By *Tahereh Manoochehrabadi*

P214 Evaluation Of Genetic Polymorphism Upstream And Downstream Of Mir-122 Gene And Their Contribution To Chronic Hepatitis B Infection, By *Maryam Lotfi*

P216 Genotype Distribution Of Hepatitis C And Hepatitis B Virus In North Of Iran, By *Maryam Lotfi*

P218 The Effects Of Single Nucleotide Polymorphism Of Il28b Gene (Rs10853728) On Treatment Response To Pegylated Interferon/Ribavirin Patients With Hepatitis C In Iran, By *Mahsa Zamanian*

P222 Comparing Anti Hepatitis B Antibody Level In Obese With Non-Obese Cases, By *Ali Kabir*

P224 Demographic Survey Of Hdv In Comparison With Hbv Among Khuzestan Province, By *Pezhman Alavinejad*

P225 Viral Hepatitis: Aeromedical Concerns And Waiver Considerations On Military Aviators, By *Ahmad Ebadi*

P226 Real-Life Practice In The Management Of Chronic Hepatitis C; A Single-Center Report From The Comprehensive Hepatitis Registry (Chr), Isfahan, Iran, By *Behrooz Ataei*

P234 Molecular Characterization Of The Transfusion Transmitted Virus (Ttv) Infection Among Chronic Hbv Patients In Golestan Province; Iran, By *Sareh Zhand*

P238 Hepatitis E Virus Antibody And Rna Prevalence In Thalassemic Patients With Hepatitis C Infection, By *Azadeh Dalvand*

P240 Natural Products And Chronic Hepatitis C Virus: Systematic Review, By *Mohammadreza Noras*

P241 Effect Of Lactoferrin In Patients With Chronic Hepatitis C: Systematic Review, By *Mohammadreza Noras*

P245 Molecular And Serological Detection Of Hepatitis E Virus In Thalassemic Patients, By *Najmeh Dalvand*

P249 Investigation Of The Association Between Interleukin 17 (Rs2397084 And Rs763780) Gene Polymorphisms And Chronic Hepatitis C Virus Infection, By *Hamideh Tayefi*

- P251 Prevalence Of Hbv, Hcv And Hbs Ag Serological Markers In Lean Versus Obese Patients With Non-Alcoholic Fatty Liver Disease, By *Behnam Honarvar*
- P255 The Concept Of Hepatitis In Medieval Iranian Medicine, By *Mohammadreza Noras*
- P256 Knowledge Of Universal Precautions Toward Hbv And Hcv Among Health Care Workers At The University Teaching Hospitals In Guilan, Iran, By *Farahnaz Joukar*
- P258 Accuracy Of Fibroscan Performance In Evaluation Of Liver Fibrosis Among Patients With Nash, By *Masoudreza Sohrabi*
- P262 Profound Anti-Fibrotic And Anti-Proliferative Effects Of Sillibin A On Activated Human Hepatic Stellate Cell, By *Seyed Younes Hosseini*
- P266 Study To Determine The Incidence Of Needle Stick And Anti-Hepatitis B Level Antibody And The Antigen Source Of Exposure In Health Workers One Of Hospital Affiliated With The University Of Medical Sciences Of Urmia In 1392, By *Mahnaz Mohammadpouri*
- P271 Survey On Frequency Of D Hepatitis In Patients With B Hepatitis Referred To Gastrointestinal And Liver Disease Research Center In Guilan, By *Fariborz Mansour-Ghanaei*
- P272 Public Preferences For Allocation Of Donated Livers For Transplantation: A Conjoint Analysis, By *Ahmad Danesh*
- P273 Hepatitis B Surface Antigen (Hbsag) Prevalence Among Urban Pregnant Women Vaccinated At Birth, By *Tahmineh Biazar*
- P275 Viral Hepatitis: The Most Common Indication For Liver Transplant In Mashhad, By *Kambiz Akhavan Rezayat*
- P276 Epidemiology Of Viral Hepatitis In North Of Iran; A Population Based Study, By *Masoudreza Sohrabi*
- P279 Anti-Hepatitis E Antibody In Hemodialysis Patients In Isfahan, Iran: Prevalence And Risk Factors, By *Behrooz Ataei*
- P287 Seroprevalence Of Hepatitis A Virus And Hepatitis E Virus In Khuzestan Province, Southwest Iran: A Systematic Review, By *Amir Pouremamali*
- P293 Prevalence And Risk Factors Of Hepatitis C Infection In Birjand, By *Azadeh Ebrahimzadeh*
- P297 The Frequency Of Afp, Ca15-3, Ca125 And Ca19-9 In Patients With Hepatitis B And C, *Sara Yeganeh Amirkandeh*
- P298 Determination Of Hepatitis E Virus Seroprevalence Among Blood Donors In South Of Iran (Bushehr), By *Gholamreza Khamisipour*
- P300 Wilson Disease, By *Hassan Dastsooz*
- P301 Identification Of Conserved Amino Acids Across Wilson Disease Gene: Useful Approach Before Mutation Detection Analysis, By *Hassan Dastsooz*

P306 Prevalence Of Non-Alcoholic Fatty Liver Disease In Morbidly Obese Patients Undergoing Sleeve Bariatric Surgery In Iran And Association With Other Comorbid Conditions, By *Shahriar Najafzadeh-Sari*

P309 Hematologic Changes Following Treatment Of Chronic Hcv Infection With Interferon Based Regimen: A Common But Safe Side Effect, By *Zahra Ahmadinejad*

P310 The Correlation Between Non-Alcoholic Fatty Liver Disease And Coronary Artery Disease In Patients Undergone Coronary Angiography In Iran, By *Hamidreza Karimi-Sari*

P311 A Randomized Controlled Trial Of Two Schedules Of Hepatitis B Vaccination In Predialysed Chronic Renal Failure Patients, By *Zahra Khazaeipour*

### درباره کنگره آنلاین رادین

مفتخریم که برای اولین بار در ایران و خاورمیانه اقدام به برگزاری کنگره به صورت کاملاً آنلاین و الکترونیکی نماییم. ثبت نام آنلاین، ثبت ساعت حضور و خروج آنلاین، اطلاع رسانی به صورت کاملاً پیشرفته و الکترونیکی و همچنین دریافت تمامی اطلاعات کنگره با سرعت بالا بر روی تلفن همراه حاضرین کنگره از مهمترین مشخصه های این سیستم می باشد.



نحوه استفاده از سیستم به این صورت می باشد که در زمان ورود به کنگره با روشن نمودن WiFi خود و متصل نمودن آن به گزینه Congress Online به صورت Automatic صفحه خوش آمدگویی نمایان می شود. همچنین با فشردن دکمه دبیرخانه و اطلاع رسانی کنگره در صفحه خوش آمدگویی به بخش ثبت نام و اطلاع رسانی منتقل می شوید

• در صورتی که امکان استفاده از سیستم WiFi بر روی تلفن همراه مقدور نمی باشد می توانید از سیستم های کامپیوتری مستقر در روز کنگره استفاده نمایید.



### اطلاع رسانی کنگره و همچنین دریافت تمامی اطلاعات اجرایی کنگره در این بخش سازماندهی شده است

**Time Table:** نمایش آنلاین برنامه زمانی کنگره شامل ساعت سخنرانی، عنوان سخنرانی، سخنران ها در تمامی سالن های کنگره نمایش داده می شود و همچنین از مهمترین نکات آن می توان به امکان دریافت فایل ارائه سخنران و همچنین فایل صوتی سخنرانی با سرعت بسیار بالا بر روی دستگاه متصل شده اشاره نمود.

**Download:** تمامی فایل های اصلی کنگره مانند کتابچه، بروشور و کاتالوگ های اختصاصی کنگره در این بخش قرار می گیرد که امکان دریافت بر روی دستگاه متصل شده را با سرعت بسیار بالا امکان پذیر می کند.

**Application:** نرم افزار های مورد نیاز به منظور استفاده از این سیستم و باز نمودن فایل های مربوطه در این بخش سازماندهی شده است.

**News:** اخبار و رویدادهای مهم انجام شده در روزهای کنگره در این بخش نمایش داده می شود و امکان اشتراک گذاری این مطالب و ارسال به افراد نیز امکان پذیر خواهد بود.

**Best File:** امکان دریافت فایل های مربوطه مانند کاتالوگ شرکت های همکار، بروشور غرفه های نمایشگاهی، اعلانات و اطلاعات، تیزرهای تبلیغاتی و ... در این بخش امکان پذیر می باشد.



6<sup>th</sup> International Tehran Hepatitis Conference

همچنین در این بخش امکانات ویژه دیگری نیز وجود دارد که مهمترین آنها شامل موارد زیر می شود .

**ارسال Notification:** امکان ارسال پیام متنی ، فایل صوتی ، کاتالوگ و ... به تمامی افراد حاضر که در حال استفاده از سیستم می باشد با استفاده از ارسال فلش انجام خواهد پذیرفت .

**ارسال پیامک :** مهمترین رویدادها اصلی کنگره با استفاده از پیام متنی برای تمامی افراد ثبت نام شده در روزهای کنگره ارسال خواهد شد .

**اتوماسیون تغذیه :** بعد از ثبت نام نهایی در کنگره به افراد بر اساس روزهای تعیین شده کنگره ژتون غذا اختصاص داده می شود که در زمان ورود به منظور صرف غذا توسط مسئول کنترل تغذیه کد ملی بررسی می شود .

- در هر روز هر فرد امکان صرف ۱ ژتون را دارد .

- امکان بررسی ژتون غذا با استفاده از کارت ملی و دستگاه بارکد خوان به منظور تسریع در امور سرویس دهی نیز امکان پذیر می باشد .



**در این بخش تمامی امور مربوط به دبیرخانه آنلاین انجام خواهد شد .**

**Register:** در این بخش پیش ثبت نام حضور در کنگره انجام خواهد پذیرفت (ثبت نام نهایی بعد از پرداخت انجام می شود) و اطلاعاتی همچون نام، نام خانوادگی، کد ملی، تلفن همراه، کشور، و پست الکترونیک را دریافت می نماید و بعد از بررسی صحت اطلاعات و تایید آن ، پیام مناسب نمایش داده شده و همچنین پیامکی حاوی تایید ثبت نام ارسال می شود.  
**Pay:** به منظور ثبت نام نهایی بایستی عملیات پرداخت صورت گیرد که امکان پرداخت با روش های ذیل امکان پذیر می باشد :

- **درگاه الکترونیکی :** با ورود کد ملی و انتخاب گروه قیمت قابل پرداخت نمایش داده خواهد شد که با استفاده از کارت های عضو شتاب قابل پرداخت خواهد بود .
  - **کد USSD :** با شماره گیری شماره ارائه شده در روز کنگره به طور مثال (\*۱۲۳#) و وارد نمودن کد ملی و انتخاب گروه امکان پرداخت الکترونیکی نیز امکان پذیر خواهد بود .
  - **دستگاه POS :** همچنین با استفاده از دستگاه های POS مستقر در بخش صندوق امکان پرداخت امکان پذیر می باشد و تایید نهایی بایستی توسط مسئول صندوق انجام شود .
  - **نقدی :** همچنین با پرداخت نقدی در بخش صندوق نیز امکان ثبت نام نهایی وجود خواهد داشت که تایید نهایی توسط مسئول صندوق امکان انجام می شود .
- بعد از پرداخت به شیوه های بالا پیامک حاوی تایید پرداخت و ثبت نام نهایی برای فرد ثبت نام شده ارسال خواهد شد .

**Enter at:** با استفاده از این گزینه در بازه زمانی مشخص شده بر اساس مقررات کنگره با ورود کد ملی تایید شده خود امکان ثبت ساعت حضور امکان پذیر خواهد بود و در انتهای پیام ثبت ساعت حضور و همچنین پیامک حاوی تایید برای فرد ارسال می گردد .

- هر دستگاه متصل شده امکان ثبت تنها یک کد ملی را در کنگره دارد .

- این بخش مختص کسانی می باشد که ثبت نام نهایی آنها انجام شده باشد .

- امکان ثبت تنها یک ساعت حضور در روز امکان پذیر می باشد .

**Leave at:** همچنین از این گزینه در بازه زمانی مشخص شده امکان ثبت ساعت خروج در کنگره نیز

امکان پذیر می باشد و بعد از نمایش پیغام مناسب ثبت نهایی ، پیامک حاوی ثبت نهایی ساعت خروج نیز برای فرد ارسال می شود.

- هر دستگاه متصل شده امکان ثبت تنها یک کد ملی را در کنگره دارد.


- این بخش مختص کسانی می باشد که ثبت نام نهایی آنها انجام شده باشد .

- امکان ثبت تنها یک ساعت خروج در روز امکان پذیر می باشد .

**Lookup:** یکی از کلیدی ترین بخش های سامانه این گزینه می باشد که در صورت عدم نمایش و دریافت پیغام مناسب و همچنین نمایش وضعیت حضور در کنگره با وارد نمودن کد ملی تمامی اطلاعات ثبت شده در کنگره نمایش داده می شود و به عبارتی صفحه شخصی هر فرد در کنگره می باشد .

**Support:** به منظور ارائه هر گونه پرسش و یا درخواست پشتیبانی آنلاین می توان با استفاده

از این گزینه سوال خود را ارسال نمود و کارشناسان حاضر در کنگره در اسرع وقت به سوال مربوطه پاسخ خواهند داد و با استفاده از سیستم کاربری و همچنین پیامک پاسخ قابل دریافت می باشد .



*Aware Today, Alive Tomorrow*

*27 - 30 May 2015*

*6<sup>th</sup> International Tehran Hepatitis Conference*

